首页 社会内容详情
博彩网址平台:Sanofi ends cancer drug trials

博彩网址平台:Sanofi ends cancer drug trials

分类:社会

网址:

SEO查询: 爱站网 站长工具

点击直达

博彩网址平台www.99cx.vip)是一个开放皇冠体育网址代理APP下载、皇冠体育网址会员APP下载、皇冠体育网址线路APP下载、皇冠体育网址登录APP下载的官方平台。博彩网址平台上博彩网址平台会员登录线路、博彩网址平台代理网址更新最快。博彩网址平台开放皇冠官方会员注册、皇冠官方代理开户等业务。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

皇冠最新登陆网址www.hg108.vip)实时更新发布最新最快的皇冠最新登陆代理线路网址、皇冠最新登陆会员线路网址、皇冠最新备用登录网址、皇冠最新手机版登录网址。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。
 当前暂无评论,快来抢沙发吧~

发布评论